Clinical Trial

68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI

Completed Phase 2
View on ClinicalTrials.gov →
Summary
68Ga-P16-093 is a novel radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-P16-093 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-30.
Status change: Recruiting → Completed 2026-07-01
Trial Details
NCT Number NCT07209865
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Prostate Cancer (Adenocarcinoma)
Enrollment 82 participants
Start Date 2024-10-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-20 (estimated)
Updated on ClinicalTrials.gov 2026-07-06